Scroll for more

About

 

Andrew Smith
Chief Financial Officer

 

Mr. Smith became our Chief Financial Officer in February 2015 after joining Sucampo in February 2011, first as Principal Accounting Officer and then as Vice President of Operations and Finance starting in January 2012. In addition to his direct role at the company, he was a financial consultant to Sucampo from June 2009 to February 2011.

Prior to  joining Sucampo, Mr. Smith was the Finance Director and Company Secretary for Retroscreen Virology Ltd., a contract virology company carrying out clinical and preclinical studies for pharmaceutical companies developing influenza vaccines, from 2006 to 2009. He also served as the Finance Director and Company Secretary of Clearlab Europe, a division of 1-800 Contacts Inc., following its acquisition of VisionTec CL, developer of the world’s first daily disposable contact lens, of which he was co-founder and member of its Board of Directors. In addition, he previously held senior financial management positions at Biocompatibles plc, Hydron Ltd (acquired by Biocompatibles) and Allergan Inc.

Mr. Smith is a member of the Board of Directors of the Tech Council of Maryland (TCM).

Mr. Smith is a Fellow of the Chartered Institute of Management Accountants and a Chartered Global Management Accountant.

Mr. Smith studied business and accounting at Liverpool John Moores University and Durham University Business School.

 
Contact Us
 
Tel: +1-301-961-3400
 

Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.